|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Keros Therapeutics, Inc. (KROS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
33,980,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Keros Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders. Co.'s primary protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Co.'s primary small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance. Co.'s product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
80,000 |
127,950 |
| Total Sell Value |
$0 |
$0 |
$3,675,839 |
$5,114,339 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
3 |
5 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ordonez Claudia |
Chief Medical Officer |
• – – |
2021-02-11 |
4 |
OE |
$0.48 |
$480 |
D/D |
1,000 |
1,000 |
|
- |
|
| Lachey Jennifer |
Chief Scientific Officer |
• – – |
2021-02-11 |
4 |
AS |
$62.85 |
$344,017 |
D/D |
(5,300) |
27,991 |
|
- |
|
| Lachey Jennifer |
Chief Scientific Officer |
• – – |
2021-02-11 |
4 |
OE |
$0.30 |
$1,590 |
D/D |
5,300 |
33,291 |
|
- |
|
| Knowles Julius |
Director |
– • – |
2021-02-11 |
4 |
AS |
$62.79 |
$749,441 |
I/I |
(11,561) |
453,878 |
|
- |
|
| Pontifax Late Stage Gp Ltd. |
10% Owner |
– – • |
2020-11-17 |
4 |
B |
$50.00 |
$3,000,000 |
I/I |
60,000 |
155,262 |
1.5 |
- |
|
| Knowles Julius |
Director |
– • – |
2020-04-13 |
4 |
B |
$20.98 |
$24,987 |
D/D |
1,191 |
1,191 |
2.39 |
- |
|
| Seehra Jasbir |
Chief Executive Officer |
• • – |
2020-04-13 |
4 |
B |
$16.00 |
$320,000 |
D/D |
20,000 |
243,856 |
2.81 |
- |
|
| Seehra Jasbir |
Chief Executive Officer |
• • – |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,169 |
223,856 |
|
- |
|
| Kariv Tomer |
Director |
– • • |
2020-04-13 |
4 |
B |
$16.00 |
$6,999,984 |
I/I |
437,499 |
149,262 |
2.25 |
- |
|
| Kariv Tomer |
Director |
– • • |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,545,100 |
105,512 |
|
- |
|
| Knowles Julius |
Director |
– • – |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
915,725 |
458,442 |
|
- |
|
| Lazarus Alon |
Director |
– • • |
2020-04-13 |
4 |
B |
$16.00 |
$1,920,000 |
I/I |
120,000 |
2,013,102 |
2.25 |
- |
|
| Lazarus Alon |
Director |
– • • |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
1,893,102 |
1,893,102 |
|
- |
|
| Nussbaum Ran |
Director |
– • • |
2020-04-13 |
4 |
B |
$16.00 |
$6,999,984 |
I/I |
437,499 |
149,262 |
2.25 |
- |
|
| Nussbaum Ran |
Director |
– • • |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,545,100 |
105,512 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2020-04-13 |
4 |
B |
$16.00 |
$6,003,200 |
I/I |
375,200 |
1,119,812 |
2.1 |
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
893,534 |
148,922 |
|
- |
|
| Pontifax Late Stage Gp Ltd. |
10% Owner |
– – • |
2020-04-13 |
4 |
B |
$16.00 |
$6,999,984 |
I/I |
437,499 |
149,262 |
1.5 |
- |
|
| Pontifax Late Stage Gp Ltd. |
10% Owner |
– – • |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,545,100 |
105,512 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2020-04-13 |
4 |
B |
$16.00 |
$6,003,200 |
I/I |
375,200 |
1,119,812 |
2.1 |
- |
|
| Gordon Carl L |
Director |
– • – |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
893,534 |
148,922 |
|
- |
|
| Arkin Moshe |
10% Owner |
– – • |
2020-04-13 |
4 |
B |
$16.00 |
$1,920,000 |
D/D |
120,000 |
2,013,102 |
2.45 |
- |
|
| Arkin Moshe |
10% Owner |
– – • |
2020-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,893,102 |
1,893,102 |
|
- |
|
| Seehra Jasbir |
Chief Executive OfficerOfficer |
• • – |
2020-04-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
212,687 |
|
- |
|
| Kariv Tomer |
Director |
– • • |
2020-04-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
751,908 |
|
- |
|
130 Records found
|
|
Page 5 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
